Mondrian Investment Partners LTD Sells 4,341,214 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Mondrian Investment Partners LTD decreased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 35.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,738,748 shares of the company’s stock after selling 4,341,214 shares during the quarter. Mondrian Investment Partners LTD’s holdings in Takeda Pharmaceutical were worth $108,342,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of TAK. Capital Research Global Investors raised its position in shares of Takeda Pharmaceutical by 3.6% during the 4th quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after buying an additional 503,446 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical by 21.1% in the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock worth $26,408,000 after buying an additional 356,069 shares during the period. OLD Mission Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after acquiring an additional 973,935 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Takeda Pharmaceutical by 1.7% during the 4th quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock valued at $11,053,000 after acquiring an additional 12,756 shares during the period. Finally, Cowen AND Company LLC bought a new position in Takeda Pharmaceutical during the 2nd quarter worth approximately $6,866,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $14.85 on Wednesday. The stock has a market capitalization of $47.25 billion, a P/E ratio of 27.00, a price-to-earnings-growth ratio of 0.27 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $16.39. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. The business’s 50 day simple moving average is $14.23 and its two-hundred day simple moving average is $13.74.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $7.75 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. Analysts forecast that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.